KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) Enterprise Value (2016 - 2025)

West Pharmaceutical Services' Enterprise Value history spans 16 years, with the latest figure at -$484.6 million for Q4 2024.

  • For Q4 2024, Enterprise Value rose 43.25% year-over-year to -$484.6 million; the TTM value through Dec 2024 reached -$484.6 million, up 43.25%, while the annual FY2024 figure was -$484.6 million, 43.25% up from the prior year.
  • Enterprise Value for Q4 2024 was -$484.6 million at West Pharmaceutical Services, down from -$446.2 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$335.3 million in Q1 2020 and bottomed at -$898.6 million in Q3 2023.
  • The 5-year median for Enterprise Value is -$601.8 million (2024), against an average of -$633.1 million.
  • The largest annual shift saw Enterprise Value crashed 40.17% in 2020 before it soared 43.97% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$615.5 million in 2020, then fell by 23.9% to -$762.6 million in 2021, then decreased by 17.27% to -$894.3 million in 2022, then increased by 4.52% to -$853.9 million in 2023, then surged by 43.25% to -$484.6 million in 2024.
  • Per Business Quant, the three most recent readings for WST's Enterprise Value are -$484.6 million (Q4 2024), -$446.2 million (Q2 2024), and -$601.8 million (Q1 2024).